Spero Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Clinical Trial (ADAPT-PO) of Oral Tebipenem HBr versus Intravenous Ertapenem for the Treatment of Complicated Urinary Tract Infection

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach